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Abstract
Background: Maturation inhibitors are a new class of antiretroviral drugs. Bevirimat (BVM) was the first substance
in this class of inhibitors entering clinical trials. While the inhibitory function of BVM is well established, the
molecular mechanisms of action and resistance are not well understood. It is known that mutations in the regions
CS p24/p2 and p2 can cause phenotypic resistance to BVM. We have investigated a set of p24/p2 sequences of
HIV-1 of known phenotypic resistance to BVM to test whether BVM resistance can be predicted from sequence,
and to identify possible molecular mechanisms of BVM resistance in HIV-1.
Results: We used artificial neural networks and random forests with different descriptors for the prediction of BVM
resistance. Random forests with hydrophobicity as descriptor performed best and classified the sequences with an
area under the Receiver Operating Characteristics (ROC) curve of 0.93 ± 0.001. For the collected data we find that
p2 sequence positions 369 to 376 have the highest impact on resistance, with positions 370 and 372 being
particularly important. These findings are in partial agreement with other recent studies. Apart from the complex
machine learning models we derived a number of simple rules that predict BVM resistance from sequence with
surprising accuracy. According to computational predictions based on the data set used, cleavage sites are usually
not shifted by resistance mutations. However, we found that resistance mutations could shorten and weaken the
a-helix in p2, which hints at a possible resistance mechanism.
Conclusions: We found that BVM resistance of HIV-1 can be predicted well from the sequence of the p2 peptide,
which may prove useful for personalized therapy if maturation inhibitors reach clinical practice. Results of
secondary structure analysis are compatible with a possible route to BVM resistance in which mutations weaken a
six-helix bundle discovered in recent experiments, and thus ease Gag cleavage by the retroviral protease.
Background
HIV and Bevirimat
Bevirimat (BVM) [1] belongs to a new class of anti-HIV
substances that inhibit maturation of virus particles by
preventing cleavage of precursor polyprotein by the ret-
roviral protease (PR). BVM prevents the final cleavage
of precursor protein p25 to p24 and p2, hence p25 pro-
teins are accumulating in the immature virions. These
immature viral particles are not capable of transforming
to an infectious stage, and the viral replication cycle is
interrupted. A first set of mutations conferring resis-
tance to BVM were found in selection experiments with
BVM and were located at CS p24/p2 [1-4]. In clinical
phase II trials, polymorphisms in the QVT-motif of p2
were found to prevent antiretroviral activity of BVM
and were extensively studied in phenotypic resistance
assays [5-7].
Machine learning
The notion of a resistance mutation is often useful as a
first, simple approximation to describe relations between
point mutations and resistance phenotypes. However, it
is often observed that the more data become available
the more complex are the relations between genotype
and phenotype that show up. For instance, it has been
observed that mutations in the QVT motif (wild type
sequence 369-371) are preferentially associated with
resistance to BVM [8]. However, as the data analyzed in
the current study shows, the same set of mutations of
QVT to QAS can be associated with BVM resistance [5]
or susceptibility [6], depending on the mutational * Correspondence: dominik.heider@uni-due.de
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with such complex associations.
There are several machine learning methods that have
been successfully employed to this end, e.g. rule-based
methods [9], decision trees [10,11], support vector
machines [12], random forests (RFs) [13], or artificial
neural networks (ANNs) [14-16].
ANNs are universal approximators that can be used to
solve non-linear classification problems; they are prone
to overtraining if not properly set up [17,18]. RFs are
also excellent non-linear models, and in general perform
better than single decision trees (DTs) [19]. They are
less easily interpretable than DTs, although they provide
variable importance measures [20]. In contrast, rule
based systems yield rules that are well intelligible, but
often classify not optimally [21,22].
Methods
Data
Sequences of the p24/p2 region of 45 strains of HIV-1
with susceptibility or intermediate resistance to BVM
(here defined as IC50 ≤ 10) were used, and 110
sequences of resistant strains (IC50 > 10). The pheno-
type was determined in experiments in which HIV-1
was cultured in the presence of increasing concentra-
tions of BVM. The concentration of BVM inhibiting
50% of viral replication compared to cell culture experi-
ments without BVM is defined as IC50 (50% inhibitor
concentration). In general, drug resistance means
reduced inhibition of viral replication by antiretroviral
drugs, resulting in increased IC50 values. The IC50 values
of the drug resistant isolates and HIV wild type are used
to calculate resistance factors
IC
IC
50
50
()
(
BVM concentration for resistant strain
BVM concen ntration for wild type)
,
a standardized measure of HIV drug resistance. The
cut-off value of the resistan c ef a c t o ru s e dt od e f i n et h e
classes “resistant to BVM” and “susceptible to BVM”
was previously derived from data obtained in phase II
clinical trials with BVM correlating phenotypic resis-
tance and clinical response [6,7].
All data were collected from several studies that have
investigated polymorphisms in p2, especially in its
C-terminal half [1,5-7] (see additional file 1 for complete
set). Duplicated sequences in each class were removed
prior to analysis.
Multiple Sequence Alignment
Multiple sequence alignments of the sequences were
produced with clustalw [23], t-coffee [24], muscle [25],
and prank [26]. Clustalw and muscle gave very compact
alignments with a width of 21 columns and most rows
free of gaps. The alignment from t-coffee was wider by
one column, and the prank alignment much wider with
36 columns. Since clustalw and muscle gave similar
alignments, and the prank alignment led to a relatively
poor predictive performance, we restrict ourselves in the
following to reporting results based on the output of
clustalw and t-coffee (see additional files 2 and 3).
Descriptor set
It is often helpful to analyze not the sequences of amino
acids as strings of characters, but to associate with each
amino acid a numerical “descriptor” value, for instance a
value that captures a physico-chemical property of this
amino acid. Recently, it has been shown that the
descriptor set is the most critical element in classifica-
tion [27,28], and that physico-chemical descriptors out-
perform simpler descriptors [29]. In our search for a
method with maximum predictive power we tested sev-
eral numerical descriptors, including hydrophobicity
values of Kyte and Doolittle [30], molecular weight, iso-
electric point (IEP) and pKa values for each amino acid.
Moreover, we used the predicted probability for cleavage
by HIV protease as a descriptor [31]. The numerical
descriptor values for gaps from the multiple sequence
alignment are undefined ap r i o r i .W et h e r e f o r et e s t e d
three values for gaps, namely 0, -1 and an interpolated
value (mean of the two amino acid descriptor values on
both sides of gap). In the case of 0 and interpolated
values for gaps the descriptor values of the amino acids
were normalized to the interval [-1,1], and in the case of
-1 for a gap they were normalized to [0,1]. Apart from
using numerical descriptors, we also trained an RF with
the multiply aligned p2 sequences using as factors the
single letter codes of the amino acids and “-” for gaps.
Neural Networks
We used a Java implementation http://www.heatonre-
search.com/encog of neural networks with one hidden
layer and three to seven hidden neurons. Resilient pro-
pagation (Rprop) was applied as a learning rule [32]. We
used the identity function as activation function for the
input layer and the logistic function for the hidden and
output layer, respectively. We have used the logistic
function because it has been shown in recent studies
that it leads to a better generalization ability [33,34].
The weights of the ANNs were initiated by applying the
Nguyen-Widrow-method [35]. Stop-training was per-
formed in order to avoid overfitting of the neural net-
works [36].
Random Forests
As an alternative to ANNs we trained Random Forests
(RFs) [20] for the prediction of BVM resistance, using the
implementation in the randomForest package of R [37]. In
our application each RF consisted of 2000 randomly and
independently grown decision trees. When using the
trained RF for prediction, an unseen sequence was
assigned to the resistance class voted for by at least 50% of
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position, for the correct classification can be assessed by
determining the increase in misclassification rate due to
leaving this variable [20]. Furthermore, we used the rpart
package of R [37] to create single decision trees.
Rule-based systems
We used the rule-based algorithms JRip [38] and PART
[39] as implemented in R [37].
Cross-validation
All machine learning methods were validated using 100-
fold leave-one-out [40] validation to assess for the differ-
ent machine learning methods the mean prediction sen-
sitivity, specificity, and accuracy (see formulas below)
and the ability to generalize to unseen sequences. In
addition to this cross-validation, we report for RFs an
out-of-bag (OOB) error, an upper limit of the classifica-
tion error [20].
For each test in the cross-validation, the sensitivity,
specificity, and accuracy were calculated according to:
sensitivity
TP
TP FN
specificity
TN
TN FP
accuracy
TP TN
TP TN






 F FP FN 
.
with true positives TP, false positives FP, false negatives
FN and true negatives TN. Figure 1 shows sensitivities and
specificities as ROC curves (Receiver Operating Character-
istics) [41] for the non-discrete methods in our study. Table
1 gives the corresponding areas under the curve (AUC).
ROC curves were drawn with R-package ROCR [42].
Structure and cleavage-site prediction
Secondary structures of all p2 sequences of 20 or more
residues were predicted using JPred [43]. Based on sta-
tistical evidence, the secondary structure predictions did
also yield a reliability index from 0 (unreliable) through
9 (highly reliable) for each residue being in a predicted
secondary structure state.
HIV protease cleavage sites for all p2 sequences were
predicted with HIVcleave [31] based on earlier work by
Chou et al. [44].
Statistical comparison
All models were compared by applying Wilcoxon
Signed-Rank test [45] on the AUC distributions from
the 100-fold leave-one-out cross-validation runs [46].
The null hypothesis was that there are no differences
between the compared classifiers.
Results and Discussion
Prediction performance of machine learning methods
All machine learning methods were trained in various
configurations and with several descriptors as described
in methods. The prediction qualities, such as the mean
AUCs (  x ), standard deviation (sd) and coefficient of
variation (cv = sd
x  ) are shown in Table 1.
The ANNs yielded AUCs between 0.72 ± 0.036
(descriptor IEP) and 0.84 ± 0.028 (descriptor hydropho-
bicity). According to the Wilcoxon Signed-Rank test
[46] with significance level a = 0.001 the mean AUC for
descriptor molecular weight was not significantly differ-
ent from that obtained with descriptor hydrophobicity,
while all other descriptors gave significantly lower values
of mean AUC. There were no significant differences (a
= 0.001) between the mean AUCs of each descriptor
with regard to the number of hidden neurons.
RFs performed consistently better than ANNs for all
descriptors, reaching AUC values between 0.85 ± 0.003
(cleavage site prediction) and 0.93 ± 0.001 (hydrophobi-
city). Again, the best results, with only small differences,
were obtained from hydrophobicity and molecular
weight as descriptors. The OOB error with this descrip-
tor was 7.59%. For comparison, the best single decision
tree, which was created with rpart in R [37], reached a
pro forma AUC of 0.841 (see Table 1).
The RFs find the most important sequence positions
for resistance prediction in the second half of the p2
sequence, especially at sequence positions 369-376 (Fig-
ure 2) in the clustalw alignment; in the wild type
sequence this region corresponds to the motif
QVTNSATI. The two positions 370 (V in wild type) and
372 (N in wild type) have by far the highest importance
in the investigated data set. This finding is in partial
agreement with the findings of other workers who iden-
tified the QVT motif at positions 369-371 as important
[7]. Positions 363 and 364 are not as prominent in
terms of importance, although they were previously
identified as crucial [47] for resistance to BVM. The
apparently lower importance of these positions in the
current study can be explained by the nature of our
data set, which focuses on resistance mediated by base-
line mutations within the p2 region in clinical HIV
isolates.
We also trained RFs on the actual sequences, i.e. with-
out numerical descriptors. These RFs gave OOB errors
above those trained with hydrophobicities, namely of
13.55% for the t-coffee alignment and 14.84% for the
clustalw alignment. For comparison, other machine
learning methods were tested as well, including Hidden
Markov Models (HMMs) [48] and linear models. We
tested linear support vector machines (SVMs) and logis-
tic regression as implemented in R [37], and further-
more, simple perceptrons implemented in Java http://
www.heatonresearch.com/encog. All of these models
performed worse compared to the RFs. The best linear
model (AUC 0.826 ± 0.008) was a linear SVM using
hydrophobicity as a descriptor. In Table 1 we report the
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method descriptor mean AUC sd cv
RF hydrophobicity 0.927 0.001 0.001
molecular weight 0.923 0.001 0.001
IEP 0.909 0.001 0.001
pKa 0.914 0.001 0.001
cleavage site prediction 0.851 0.003 0.003
ANN hydrophobicity 0.841 0.028 0.034
molecular weight 0.839 0.022 0.026
IEP 0.721 0.036 0.050
pKa 0.733 0.028 0.038
cleavage site prediction 0.762 0.036 0.047
linear model hydrophobicity 0.826 0.008 0.009
molecular weight 0.811 0.000 0.000
IEP 0.784 0.000 0.000
pKa 0.777 0.000 0.000
cleavage site prediction 0.803 0.000 0.000
decision tree hydrophobicity 0.815 0.000 0.000
molecular weight 0.841 0.000 0.000
IEP 0.771 0.000 0.000
pKa 0.764 0.000 0.000
cleavage site prediction 0.803 0.000 0.000
JRip hydrophobicity 0.825 0.000 0.000
PART hydrophobicity 0.890 0.000 0.000
Rule372 hydrophobicity 0.710 0.000 0.000
Results of the 100-fold leave-one-out validation. The pro forma AUC values for the discrete methods (decision trees and rule based models) are just for
comparison purposes. sd: standard deviation; cv: coefficient of variation.
Figure 1 ROC curve. Averaged ROC curves of the best performing
descriptor for each (non-discrete) machine learning approach. The
standard deviation bars mark the 95% confidence intervals. blue:
SVM; green: ANN; red: RF.
Figure 2 Importance of sequence positions in RF predictions.
Importance of sequence positions in p2 for prediction of BVM
resistance by RFs. The y-axis denotes the “percental increase in
misclassification rate” [20]. The upper horizontal axis indicates wild
type sequence.
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HMMs were not able to classify the sequences. In Fig-
ure 1 the ROC-curves for the descriptors performing
best for each (non-discrete) machine learning method
are shown.
Genotype-phenotype rules
The two algorithms JRip and PART for rule extraction
provided rule sets that performed well in the cross-vali-
dation with accuracies reaching almost that of RFs.
S i n c et h er u l e sd e r i v e df r o mt h et - c o f f e ea l i g n m e n th a d
lower errors than those based on the clustalw alignment,
we here report only the former rules.
During cross-validation JRip generated most fre-
quently a set of three rules relating alignment positions,
hydrophobicities, and BVM resistance class. Translated
to amino acid residues, the rules are:
1. IF position 370 Î {I, V} AND NOT position 373
Î {K, R} AND position 374 Î {I, V, L, F, C, M, A} ⇒
susceptible
2. IF position 372 Î {K, R} AND position 373 Î {P,
H, E, N, Q, D} ⇒ susceptible
3. ELSE resistant
JRip reaches in the cross-validation a mean sensitivity
of 77.01% at a specificity of 88.14%. Dropping the first
rule leads to a sensitivity of 11.76% and a specificity of
99.21%. Dropping the second rule leads to a sensitivity
of 72.54% with a corresponding specificity of 88.1%.
In the cross-validation PART most frequently
extracted fifteen rules (see additional file 4) with a sensi-
tivity of 85.5% and a specificity of 93.27%. Remarkably,
the PART rules did take exactly those sequence posi-
tions into account that had non-zero importance in the
RF analysis (see Figure 2). As suggested by the JRip and
PART rules, resistance is generally caused by patterns of
two or more residues. However, the importance plot
(Figure 2) show that single positions may be useful indi-
cators as well. E.g. we found that at sequence position
372 the hydrophobicity values of resistant and suscepti-
ble group clustered around two different values, 0.39 for
the resistant and 0.26 for the susceptible. From this we
could derive the rule (Rule372): a sequence is resistant if
the hydrophobicity at 372 is closer to the mean hydro-
phobicity of the resistant cluster than to that of the sus-
ceptible cluster and vice versa. The rule is predictive
with 52% sensitivity and 90% specificity.
Structural and functional implications of resistance
mutations
After experiments [49] have excluded the classical mole-
cular mechanism of protease inhibition, i.e. blocking of
its catalytic site, there ares t i l ls e v e r a lm o l e c u l a r
mechanisms for BVM action considered in the literature
(for review see [1]): BVM could directly occlude the
protease cleavage site ("direct” mechanisms, possibly
with contact of BVM and protease), or it could stabilize
a Gag structure that has to be weakened or dissolved to
make the cleavage sites accessible to the protease
("indirect” mechanisms, possibly without contact of
BVM and protease). Accordingly, there are several possi-
ble resistance mechanisms discussed in the literature,
such as mutations that perturb the BVM binding site,
that weaken the mentioned Gag structure, or that make
the affected cleavage site easier digestible for the pro-
tease. A hypothetical resistance mechanism that to our
knowledge so far has not been addressed is a shift of
the cleavage site. We have therefore investigated associa-
tions of resistance mutations with cleavage site locations
properties, as predicted computationally. In all suscepti-
ble and most resistant sequences the predicted PR clea-
vage sites with maximum probability were unchanged
with respect to the wild type (see additional file 5): clea-
vage was predicted to be most probable at P1-sites 363
and 367 in agreement with experimental findings [50],
and cleavage probabilities at P1 363 were rather invari-
able across the data set. In a few resistant sequences
cleavage sites probabilities were indeed predicted to
shift (see additional file 6). Amongst these sequences we
observed a tendency for the second cleavage site at P1
367 to have lower probabilities whereas position 365 did
emerge as a new possible P1 site. However, since this
occurs rather rarely, the data do not support a shift of
the cleavage site as a major resistance mechanism. It is
notable that in the studied data the positions 372-376
most relevant for resistance (Figure 2) lie outside the
protease binding region P4-P4’ for P1 at 363 (P4’ 367).
Even for the internal cleavage site at P1 367 (P4’ 371),
more than half of these important positions are outside
the protease binding site. This finding is consistent with
a model that allows for an “indirect” mechanism of
BVM, though it cannot exclude “direct” mechanisms. In
fact, mutations found in other studies closer to the clea-
vage sites [47,49] also allow for a direct model.
A key component of an indirect mechanism is a struc-
ture within Gag that has to be weakened prior to clea-
vage of p24/p2. A candidate structure is the a-helix first
predicted by Accola et al. [50]. We have extended sec-
ondary structure predictions to all sequences of the data
set, including the wild type. All these structures were
predicted as mainly a-helical in the central part (addi-
tional file 7). This gross feature is consistent with the
experimental structure by Morellet et al. [51], though
the predicted helices are shorter. While in the Morellet
structure the helix comprises all of the residues starting
at position 358, the predicted helices comprise between
seven and twelve of the 21 sequence positions and typi-
cally start at position 361 (Figure 3A). Apart from the
deficiencies of the prediction method the difference
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to the experimental conditions [51] where a substantial
amount of trifluoroethanol in the solution could have
led to a helix content exceeding that in the native state.
The earlier work by Worthylake et al.[ 5 2 ]s u p p o r t st h e
view that the helix formed by p2 as such is not very
stable. A very stable helix at the cleavage site could pos-
sibly prevent PR from cleaving, because the protease
requires its substrate in an extended conformation [53].
On the other hand, recent data from electron micro-
scopy [54] are compatible with bundles of six p2 helices
stabilizing the immature matrix of the virus. In sum-
mary predictions and experiments point to a weak p2
helix that is stabilized by its environment.
It is remarkable that the end of the predicted helices
around position 369 coincides with start of the sequence
region most important for resistance (Figure 2) in our
data set; in other words, the sequence positions most
important for resistance in our data lie outside the
predicted a-helix in a region of unspecified secondary
structure. Moreover, the resistant sequences have a ten-
dency for shorter helices compared to susceptible
s e q u e n c e s ,a sc a nb es e e ni nt h ee a r l i e rd r o po fh e l i x
probability at around position 368 in Figure 3A.
We have also analyzed the confidence with which the
secondary structure prediction algorithm assigns resi-
dues to a helical state. If we assume that the prediction
is based on a representative sample of sequences
observed as helices and non-helices, respectively, then
this confidence could have a positive correlation with
helix stability. A comparison of resistant and susceptible
sequences with respect to mean confidence along the
helix shows that resistant sequences have a tendency to
lower helix confidence, and, if the assumption holds,
lower helix stability (Figure 3B).
The above tendencies of resistance class, predicted
helix length and confidence may reflect possible “indir-
ect” resistance mechanisms: shorter and weaker helices
Figure 3 Helix length and confidence. Secondary structure predictions for p2 with susceptibility and resistance to BVM. A: For all p2
sequences the secondary structure was predicted by JPred [43] and then for each sequence position the helix probability (fraction of helix at
this position) was computed separately for the susceptible and resistant sequences. B: Histograms of the confidence with which JPred predicts a
helix (0 lowest, 9 highest). The confidence values were averaged for each sequence over all positions predicted to be helical.
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destabilizing the binding site of BVM that may lie on
the six-helix bundle mentioned above, or by easing the
unraveling of the remaining helix, and thus cleavage by
PR in presence of BVM. This argument suggests to test
whether helix length and helix confidence are predictive
of resistance. We have therefore trained another random
forest solely with the predicted helix lengths and confi-
dences, and without reference to the detailed sequences.
This random forest had an OOB error of 23%, which is
not as good as the errors of 8-15% reported above for
random forests or rule-based methods trained on
sequence information, but still much better than ran-
dom guessing. This means that tuning of helicality of p2
could indeed be a BVM resistance mechanism.
Conclusions
BVM was the first drug of the new class of maturation-
inhibitors of HIV-1 that has reached phase II clinical
trials. Several polymorphisms in p2 of HIV-1 hampered
the sustained suppression of viral replication in these
patients and conferred phenotypic resistance [7]. Since
these polymorphisms were found in about 30% of treat-
ment naïve HIV isolates and were significantly accumu-
lated in PI resistant HIV isolates [55], genotypic
resistance testing seems to be mandatory before admin-
istration of BVM.
Our analysis has shown that with the available
sequences and corresponding phenotypic data it is pos-
sible to train machine learning methods that predict
phenotypic resistance to BVM, mediated by baseline
mutations of the p2 region, for unseen sequences with
an error of less than 10%. This result is compatible with
the view that mutations in p2 are the main reason for
BVM resistance observed in clinical isolates not
responding to BVM in clinical phase I and II studies.
The high classification accuracy is encouraging for per-
sonalized therapy based on genotypical testing in case
BVM-like drugs will become part of the antiretroviral
repertoire. With a larger, representative data set of gen-
otype-phenotype pairs, it could become feasible to use
machine learning methods not only for classification but
also for regression, i.e. prediction of quantitative resis-
tance factors.
Random forests, the method with the best classifica-
tion results amongst those tested, also allowed for the
identification of the sequence positions most relevant
for resistance. In our data set, these sequence positions
cluster in the C-terminal half of p2, mostly outside the
P4-P4’ protease binding region. This is in agreement
with the outcome of rule-based methods.
As judged from predicted cleavage positions, resis-
tance mutations do usually not shift the cleavage site.
Secondary structure prediction shows that resistance
mutations may affect the length and strength of the
a-helix formed by at least sequence positions 371-377
and covering also the cleavage site. This hypothesis is in
agreement with propositions by other workers [1] and
suggests possible resistance mechanisms that also may
occur in combination, e.g. (a) resistance mutations
could destroy the BVM binding site that may lie in the
C-terminal half of p2, formed by several p2 peptides in
the six-helix bundle suggested by Wright et al.[ 5 4 ] ;( b )
resistance mutations could weaken the a-helix in p2,
and thus, the six-helix bundle in the immature virus.
This could ease unraveling of the helix prior to cleavage
by PR, and hence, may functionally outweigh a stabiliz-
ing effect of BVM on the helix bundle.
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